Radiofrequency ablation and chemoembolization for hepatocellular carcinoma

[Guest guest]

Cancer J. 2008 Mar-Apr;14(2):117-22.

Radiofrequency ablation and chemoembolization for hepatocellular carcinoma.

Georgiades CS, Hong K, Geschwind JF.

From the *Department of Radiology, Vascular and Interventional Radiology, s

Hopkins Hospital, Baltimore, MD.

PURPOSE:: To provide an up-to-date review of the technique, efficacy, safety and

clinical applications for radiofrequency ablation (RFA) and transarterial

chemoembolization (TACE) for hepatocellular carcinoma (HCC). METHODS:: A

thorough review of the literature was performed as related to RFA and TACE for

the treatment of HCC. We mixed these findings with our own extensive research

and clinical experience on this subject by drawing from a pool of more than 1000

patients treated with both modalities. RESULTS:: TACE has been shown with the

work of Llovet, Camma, and Lo to provide a significant survival benefit for

patients with unresectable HCC. The former showed a 1-, 2-, and 3-year survival

at 57%, 31%, and 26% in the treatment group vs. 32%, 11%, and 3% in the

supportive treatment alone group, respectively. Repeatedly, RFA has been shown

to be very effective in the treatment of small (

_________________________________________________________________

Get in touch in an instant. Get Windows Live Messenger now.

http://www.windowslive.com/messenger/overview.html?ocid=TXT_TAGLM_WL_Refresh_get\

intouch_042008

[Guest guest]

Cancer J. 2008 Mar-Apr;14(2):117-22.

Radiofrequency ablation and chemoembolization for hepatocellular carcinoma.

Georgiades CS, Hong K, Geschwind JF.

From the *Department of Radiology, Vascular and Interventional Radiology, s

Hopkins Hospital, Baltimore, MD.

PURPOSE:: To provide an up-to-date review of the technique, efficacy, safety and

clinical applications for radiofrequency ablation (RFA) and transarterial

chemoembolization (TACE) for hepatocellular carcinoma (HCC). METHODS:: A

thorough review of the literature was performed as related to RFA and TACE for

the treatment of HCC. We mixed these findings with our own extensive research

and clinical experience on this subject by drawing from a pool of more than 1000

patients treated with both modalities. RESULTS:: TACE has been shown with the

work of Llovet, Camma, and Lo to provide a significant survival benefit for

patients with unresectable HCC. The former showed a 1-, 2-, and 3-year survival

at 57%, 31%, and 26% in the treatment group vs. 32%, 11%, and 3% in the

supportive treatment alone group, respectively. Repeatedly, RFA has been shown

to be very effective in the treatment of small (

_________________________________________________________________

Get in touch in an instant. Get Windows Live Messenger now.

http://www.windowslive.com/messenger/overview.html?ocid=TXT_TAGLM_WL_Refresh_get\

intouch_042008